Back
Compare AU
Compare CURE vs. BGBL
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Global X S&P Biotech ETF (CURE) and the Betashares Global Shares ETF (BGBL). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
CURE | BGBL | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 68 | 828 |
Median incremental investment | $673.61 | $2,016.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,065.46 | $8,851.36 |
Average age group | > 35 | 26 - 35 |
Key Summary
CURE | BGBL | |
|---|---|---|
Strategy | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. | BGBL.AX was created on 2023-05-09 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The investment objective of the Betashares Global Shares ETF is to provide an investment return that aims to track the performance of the Solactive GBS Developed Markets ex Australia Large & Mid Cap Index (the Index), before taking into account fees and expenses. |
Top 3 holdings | Apellis Pharmaceuticals Inc (1.80 %) Revolution Medicines Inc Ordinary Shares (1.51 %) Madrigal Pharmaceuticals Inc (1.35 %) | MSCI WORLD INDEX JUN26 (0 %) NVIDIA CORP (5.61 %) APPLE INC (4.60 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | Other (29.74 %) Information Technology (25.04 %) Financials (8.88 %) |
Top 3 countries | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) | United States (72.14 %) Japan (6.29 %) United Kingdom of Great Britain and Northern Ireland (3.69 %) |
Management fee | 0.45 % | 0.08 % |
Key Summary
CURE | BGBL | |
|---|---|---|
Issuer | Global X | BetaShares |
Tracking index | S&P Biotechnology Select Industry | Solactive GBS Developed Markets ex Australia Large & Mid Cap Index - AUD - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.45 % | 0.08 % |
Price | $65.57 | $79.03 |
Size | $41.711 million | N/A |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 5.08 % | 1.03 % |
Market | ASX | ASX |
First listed date | 12/11/2018 | 10/05/2023 |
Purchase fee | $6.50 | $6.50 |
Community Stats
CURE | BGBL | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 68 | 828 |
Median incremental investment | $673.61 | $2,016.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $2,065.46 | $8,851.36 |
Average age group | > 35 | 26 - 35 |
Pros and Cons
CURE | BGBL | |
|---|---|---|
Pros |
|
|
Cons |
|
|
CURE | BGBL |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |